Candel Therapeutics Inc (CADL): Next-Year EPS Estimate 28.85%
As of 2026-06-04, Candel Therapeutics Inc (CADL) has a next-year EPS growth estimate of 28.85%.
On 2026-05-19, analyst consensus for CADL's next-year EPS growth shifted from 29.81% to 28.85% — a negative change of 0.96 percentage points. The revised estimate has been sustained across 13 subsequent trading sessions. Current-year growth is projected at -30.37%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 28.85%
- EPS growth this year
- -30.37%
- EPS next quarter (est)
- -$0.24
- Last price
- $9.27
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 28.85% | -30.37% | -$0.24 | $9.27 |
| 2026-06-03 | 28.85% | -30.37% | -$0.24 | $8.80 |
| 2026-06-02 | 28.85% | -30.37% | -$0.24 | $8.42 |
| 2026-06-01 | 28.85% | -30.37% | -$0.24 | $8.51 |
| 2026-05-31 | 28.85% | -30.37% | -$0.24 | $8.30 |
| 2026-05-28 | 28.85% | -30.37% | -$0.24 | $8.09 |
| 2026-05-27 | 28.85% | -30.37% | -$0.24 | $8.05 |
| 2026-05-26 | 28.85% | -30.37% | -$0.24 | $7.95 |
| 2026-05-25 | 28.85% | -30.37% | -$0.24 | $7.99 |
| 2026-05-24 | 28.85% | -30.37% | -$0.24 | $7.99 |
| 2026-05-21 | 28.85% | -30.37% | -$0.24 | $7.93 |
| 2026-05-20 | 28.85% | -30.37% | -$0.24 | $7.71 |
| 2026-05-19 | 28.85% | -30.37% | -$0.24 | $7.66 |
| 2026-05-18 | 29.81% | -36.10% | -$0.24 | $7.90 |
| 2026-05-17 | 28.02% | -32.73% | -$0.23 | $8.77 |
| 2026-05-14 | 32.14% | -43.42% | -$0.25 | $8.91 |
| 2026-05-13 | 27.39% | -74.37% | -$0.30 | $8.65 |
| 2026-05-12 | 27.39% | -74.37% | -$0.30 | $8.72 |
| 2026-05-11 | 27.39% | -74.37% | -$0.30 | $8.85 |
| 2026-05-10 | 27.39% | -74.37% | -$0.30 | $8.35 |
| 2026-05-07 | 27.39% | -74.37% | -$0.30 | $7.79 |
| 2026-05-06 | 27.39% | -74.37% | -$0.30 | $7.63 |
| 2026-05-05 | 27.39% | -74.37% | -$0.30 | $7.67 |
| 2026-05-04 | 27.39% | -74.37% | -$0.30 | $7.53 |
| 2026-05-03 | 27.39% | -74.37% | -$0.30 | $6.47 |
| 2026-04-30 | 27.39% | -74.37% | -$0.30 | $6.18 |
| 2026-04-29 | 27.39% | -74.37% | -$0.30 | $6.18 |
| 2026-04-28 | 27.39% | -74.37% | -$0.30 | $6.20 |
| 2026-04-27 | 27.39% | -74.37% | -$0.30 | $6.29 |
| 2026-04-26 | 27.39% | -74.37% | -$0.30 | $6.50 |
Recent News
- Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual MeetingGlobeNewswire
- Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Candel Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Candel Therapeutics Inc (CADL) has a next-year EPS growth estimate of 28.85%, based on analyst consensus.
When was the latest EPS estimate revision for CADL?▾
The most recent revision occurred on 2026-05-19, when analysts adjusted the next-year EPS growth estimate from 29.81% to 28.85%.
What sector and industry does Candel Therapeutics Inc belong to?▾
Candel Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CADL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Candel Therapeutics Inc (CADL) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports